Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Next Previous
X
Search
Trial Profile

An 8-week, randomized, double-blind, placebo-controlled, multi-centre study of [S,S]-reboxetine administered once daily in patients with fibromyalgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 12 Nov 2024 According to Axsome Therapeutics media release, NDA submission for AXS-14 in fibromyalgia anticipated November 2024.
    • 05 Aug 2024 According to Axsome Therapeutics media release, NDA submission for AXS-14 in fibromyalgia expected 3Q 2024.
    • 06 May 2024 According to an Axsome Therapeutics media release, Pre-submission activities for the Companys NDA for AXS-14 for the management of fibromyalgia are nearing completion. NDA submission for AXS-14 in fibromyalgia expected in 2Q 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top